Equibles does not estimate personal net worth.
Get an email with a short summary when Jazz Pharmaceuticals plc publishes a filing, an earnings call transcript or a press release.
Get JAZZ alertsRenee Gala is recorded as CEO and Board Member at Jazz Pharmaceuticals plc (JAZZ) since August 11, 2025 and COO at Jazz Pharmaceuticals plc (JAZZ). The newest filing on record that lists Renee Gala as COO at Jazz Pharmaceuticals plc (JAZZ) is dated June 14, 2024. Jazz Pharmaceuticals plc reported in an 8-K filed July 10, 2025 that Renee Gala was appointed Class I director, effective August 11, 2025. Jazz Pharmaceuticals plc reported in an 8-K filed July 10, 2025 that Renee Gala was appointed President & Chief Executive Officer, effective August 11, 2025. The proxy statement of Jazz Pharmaceuticals plc reports total compensation of $6,628,888 for Renee Gala in fiscal 2024, including a base salary of $824,923. Disclosed compensation is on record for 5 fiscal years. Renee Gala has spoken on 25 earnings calls across 1 company, most recently for Jazz Pharmaceuticals plc on May 5, 2026. Jazz Pharmaceuticals plc is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Jazz Pharmaceuticals plc includes Bruce Cozadd (CEO and Board Member), Renee D. Gala (CEO), Matthew P. Young (CFO) and 7 others.
“the Board approved an increase in the number of directors constituting the full Board from 12 to 13 and, upon the recommendation of its nominating and corporate governance committee, appointed Ms. Gala to the Board, effective as of August 11, 2025, as a Class I director for a term expiring at the annual general meeting of shareholders to be held in 2027.”
“On July 8, 2025, the Board of Directors (the "Board") of Jazz Pharmaceuticals plc (the "Company"), appointed Renee Gala, the Company's President and Chief Operating Officer, as the Company's President & Chief Executive Officer, effective as of August 11, 2025.”
“Building on our record year in 2025, we are pleased to share our results from an exceptionally strong first quarter led by commercial execution across our highly differentiated products for sleep, epilepsies, and cancers.”
“Good afternoon, everyone, and thank you for joining us to discuss JAZZ's fourth quarter and full year 2025 results, as well as our outlook for 2026. I'll begin on slide five.”
“Good afternoon, everyone, and thank you for joining us to discuss Jazz's third quarter 2025 results. I'm delighted to be speaking with you today as Jazz's CEO. The past 3 months have been energizing and productive.”
“I'm thrilled to be stepping into the CEO role to build upon Jazz's incredible success and transformation over the last several years. I'd like to thank the Board for their trust and confidence in me and Bruce for his dedicated leadership of Jazz over the past 2 decades.”
“I'll begin on Slide 7 to discuss the continued progress of our commercial portfolio, starting with our sleep therapeutic area.”
2025-08-11–present
2025-08-11–present
Start not stated–present
Last confirmed June 14, 2024
Start not stated–2023-06-16
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
COO, CEO, Board Member
2025-08-11–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2024 | Jazz Pharmaceuticals plc (JAZZ) | President and COO | $824,923 | $6,628,888 |
| 2023 | Jazz Pharmaceuticals plc (JAZZ) | President and COO | $767,719 | $5,434,388 |
| 2022 | Jazz Pharmaceuticals plc (JAZZ) | President and COO | $690,357 | $5,029,436 |
| 2021 | Jazz Pharmaceuticals plc (JAZZ) | President and COO | $616,923 | $4,605,224 |
| 2020 | Jazz Pharmaceuticals plc (JAZZ) | Executive Vice President and CFO | $484,616 | $4,123,400 |
